Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
NCT05267535 · Neurim Pharmaceuticals Ltd. · PHASE2/PHASE3 · terminated · last registry update 2026-09-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.” | – | Registry record, Neurim Pharmaceuticals Ltd. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-28Phase 3 first posted: Ain Shams University, Melatonin + Midazolam (NCT07900321)
- 2026-10-27Results posted on the registry: Duke University, Astaxanthin + Protandim (NCT06429059)
- 2026-10-22Results posted on the registry: Duquesne University, Melatonin 5 mg + Placebo (plant fiber) for melatonin (NCT04233112)
- 2026-10-08Phase 3 first posted: Menoufia University, Melatonin + Placebo (NCT07865988)
- 2026-08-21Results posted on the registry: University of Cincinnati, a drug against MTNR1A (NCT04724668)
- 2026-07-23Phase 3 first posted: Ain Shams University, Melatonin (NCT07721324)
- 2026-06-17Phase 3 first posted: University of Child Health Sciences and Children's Hospital, Lahore, MgSO4 (seizure prevention) + Melatonin , Mgso4 (NCT07652801)
- 2026-05-08Phase 3 first posted: Assistance Publique Hopitaux De Marseille, Pediatric Prolonged-Released Melatonin (PedPRM) + Placebo (NCT07576764)
- 2026-03-31Phase 3 first posted: Ain Shams University, Melatonin (NCT07503600)
- 2026-02-20Also stopped (terminated): Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Melatonin (NCT03540485)
- 2026-02-18Phase 3 first posted: University Hospital, Strasbourg, France, pediatric, prolonged released melatonin + Placebo (NCT07418554)
- 2026-02-12Results posted on the registry: Brigham and Women's Hospital, placebo (NCT02642640)
- 2026-02-04Results posted on the registry: M.D. Anderson Cancer Center, Methylphenidate Hydrochloride + Therapeutic Melatonin (NCT01628029)
- 2026-01-13Phase 3 first posted: Emory University, Zolpidem (NCT07336277)
- 2026-01-13Phase 3 first posted: Ain Shams University, Melatonin group + Midazolam group (NCT07336095)
- 2025-12-24Also stopped (withdrawn): University of Colorado, Denver, a drug against MTNR1A (NCT06292000)
- 2025-10-14Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT04868539)
- 2025-10-09Also stopped (terminated): Brigham and Women's Hospital, Tasimelteon (NCT05922995)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision